Gemcitabine treatment causes resistance and malignancy of pancreatic cancer stem-like cells via induction of lncRNA HOTAIR

Gemcitabine is the first-line chemotherapeutic agent for advanced adenocarcinoma of the pancreas, despite the high risk of chemoresistance as a major disadvantage. In the past few years, significant advances have been made in the field of pancreatic cancer stem-like cells (CSCs) and their critical r...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Li, Dong, Ping, Wang, Weiguo, Huang, Mingquan, Tian, Bole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704340/
https://www.ncbi.nlm.nih.gov/pubmed/29201179
http://dx.doi.org/10.3892/etm.2017.5151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704340/
https://www.ncbi.nlm.nih.gov/pubmed/29201179
http://dx.doi.org/10.3892/etm.2017.5151

Ejemplares similares